Horn Kinney 4

What Happened Horn Kinney, Chief Business Officer of Immunome (IMNM), exercised 1,092 stock options on July 7, 2026 at $12.92 per share (total exercise cost $14,109) and the same day sold those 1,092 shares in the open market at $25.00 per share for total proceeds of $27,300. The filing also records the derivative conversion (M) tied to the exercise. The transactions were executed under a pre-established Rule 10b5-1 trading plan.

Key Details

• Transaction date: July 7, 2026.
• Exercise: 1,092 shares at $12.92 — total cost $14,109.
• Sale: 1,092 shares at $25.00 — total proceeds $27,300.
• Net result (gross, before taxes/fees): proceeds $27,300 − cost $14,109 ≈ $13,191.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnotes: F1 — sales effected pursuant to a Rule 10b5-1 plan adopted March 30, 2026. F2 — option vesting: 25% vested Aug 9, 2025; remaining shares vest monthly over three years.
• Filing timeliness: Form 4 filed July 9, 2026 (timely within the usual two-business-day window).

Context This was an option exercise followed by an immediate open-market sale (a common "exercise-and-sell" or cashless-like outcome). The 10b5-1 plan note indicates the sales were pre-arranged, which often means trades were executed according to a pre-set schedule rather than as a spontaneous market-timing decision. As always, these transactions disclose the mechanics and proceeds but do not by themselves explain the insider’s broader view of the company.